Overcoming R&D Tax Credit Challenges in Life Sciences
From clinical trials to regulatory submissions, biomedical R&D is complex and heavily documented. Tracking qualified expenses across systems, teams, and protocols is time-consuming and easy to miss. Boast automates this process, ensuring claims are accurate, compliant, and complete without slowing down innovation.
Supporting Regulated R&D in Life Sciences
Biomedical innovation requires more than invention. It also demands adherence to quality systems, documentation protocols, and health authority guidelines. Boast helps teams stay compliant with frameworks like GLP, GCP, FDA, and EMA by producing audit-ready documentation aligned with your internal regulatory and quality processes.
Common R&D Activities That Qualify in Life Sciences
Life sciences and biomedical companies often overlook eligible R&D tax credit activities because they seem like “routine work.”
Boast helps you identify qualifying efforts such as:
Clinical research, preclinical and trial design
Drug formulation, biocompatibility testing, or biomarker development
Development of custom lab equipment, prototypes, or medical devices
Software development for bioinformatics or digital health tools
Regulatory submissions supported by experimentation and validation work
Who We Help in the Biomedical Industry
Boast supports a wide range of biomedical organizations – whether you’re developing new therapeutics, designing medical devices, or advancing digital health solutions. We work with companies across the innovation lifecycle, including:
Why R&D Tax Credits Matter More Than Ever in Life Sciences
Access to capital in life sciences is critical. Funding cycles can be long, competition is intense, and innovation timelines are often unpredictable. R&D tax credits offer a strategic way to extend your financial runway without giving up equity or delaying key development milestones.
You might be building the next generation of biologics or refining a diagnostic platform. Boast helps you turn existing work into non-dilutive capital that can be reinvested in product development, hiring, and growth.
